Design of Polarity-Dependent Immunosensors Based on the Structural Analysis of Engineered Antibodies.


Journal

ACS chemical biology
ISSN: 1554-8937
Titre abrégé: ACS Chem Biol
Pays: United States
ID NLM: 101282906

Informations de publication

Date de publication:
18 08 2023
Historique:
medline: 21 8 2023
pubmed: 13 7 2023
entrez: 13 7 2023
Statut: ppublish

Résumé

"Reagentless" immunosensors are emerging to address the challenge of practical and sensitive detection of important biomarkers in real biological samples without the need for multistep assays and user intervention, with applications ranging from research tools to point-of-care diagnostics. Selective target binding to an affinity reagent is detected and reported in one step without the need for washing or additional reporters. In this study, we used a structure-guided approach to identify a mutation site in an antibody fragment for the polarity-dependent fluorophore, Anap, such that upon binding of the protein target cardiac troponin I, the Anap-labeled antibody would produce a detectable and dose-dependent shift in emission wavelength. We observed a significant emission wavelength shift of the Anap-labeled anti-cTnI mutant, with a blue shift of up to 37 nm, upon binding to the cTnI protein. Key differences in the resulting emission spectra between target peptides in comparison to whole proteins were also found; however, the affinity and binding characteristics remained unaffected when compared to the wild-type antibody. We also highlighted the potential flexibility of the approach by incorporating a near-infrared dye, IRDye800CW, into the same mutation site, which also resulted in a dose-dependent wavelength shift upon target incubation. These reagents can be used in experiments and devices to create simpler and more efficient biosensors across a range of research, medical laboratory, and point-of-care platforms.

Identifiants

pubmed: 37440171
doi: 10.1021/acschembio.3c00303
doi:

Substances chimiques

Antibodies 0
Peptides 0
Immunoglobulin Fragments 0
Troponin I 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1863-1871

Subventions

Organisme : NIBIB NIH HHS
ID : K99 EB033580
Pays : United States

Auteurs

Jiaul Islam (J)

Department of Chemical and Biological Engineering, Monash University, Melbourne 3800, Australia.

Paul Conroy (P)

Dept. of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne 3800, Australia.

Christian Fercher (C)

Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane 4072, Australia.
ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane 4072, Australia.

Mijin Kim (M)

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Centre, New York 10065, United States.

Zvi Yaari (Z)

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Centre, New York 10065, United States.
School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91905, Israel.

Martina Jones (M)

Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane 4072, Australia.
ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane 4072, Australia.

Toby D M Bell (TDM)

School of Chemistry, Monash University, Melbourne 3800, Australia.

Tom Caradoc-Davies (T)

Dept. of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne 3800, Australia.
Australian Synchrotron - ANSTO, Melbourne 3168, Australia.

Ruby Law (R)

Dept. of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne 3800, Australia.

James Whisstock (J)

Dept. of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne 3800, Australia.

Daniel Heller (D)

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Centre, New York 10065, United States.

Stephen Mahler (S)

Dept. of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne 3800, Australia.
Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane 4072, Australia.

Simon Corrie (S)

Department of Chemical and Biological Engineering, Monash University, Melbourne 3800, Australia.

Articles similaires

Animals Huntington Disease Mitochondria Neurons Mice
Animals Adjuvants, Immunologic Mice Antigen-Presenting Cells Antigen Presentation
Hemolysin Proteins Artificial Cells Protein Engineering Protein Transport Cell Membrane
Substrate Specificity Peptides Catalysis Hydrolysis Protein Conformation

Classifications MeSH